Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CureVac BV
Plus: Valneva confirms supply deal with the UK government for its inactivated vaccine candidate; Humanigen expands manufacturing ahead of Phase III data.
A choice asset in the middle of a pandemic, pharma companies could see the investment bubble burst once normalcy is on the horizon. But interest will continue in innovators, rather than big pharma specifically, predicts an expert panel featuring Biogen's chairman, a former Sanofi CEO and an ex-NIH director.
Companies in talks with EU authorities for the supply of at least 200 million initial doses of their mRNA vaccine. Plus, other new partnerships around the world and an India pause for AstraZeneca's contender in line with global decision.
Convalescent plasma has taken another battering as a potential treatment for coronavirus patients, after a UK drug safety body agreed with a US expert panel that there was not yet enough evidence to recommend its use in COVID-19 patients.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- CureVac GmbH